Author: Boehringer Ingelheim
The National Pharmaceutical Regulatory Agency (NPRA) Malaysia has approved Spesolimab (marketed as SPEVIGO®) for the treatment of flares in adults with generalized pustular psoriasis (GPP), the first indicated treatment of its kind in Malaysia.
Log In or Register as a healthcare professional to read the full article.
Copyright © Medical Channel Asia 2024.
All rights reserved.
The contents on Medical Channel Asia are for general educational purposes only.
It is not intended to be a substitute for professional medical advice, treatment, or diagnosis.
See additional information.
The contents on Medical Channel Asia are for general educational purposes only.
It is not intended to be a substitute for professional medical advice, treatment, or diagnosis.
See additional information.